Quantinno Capital Management LP boosted its position in Perrigo Company plc (NYSE:PRGO – Free Report) by 105.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 19,695 shares of the company’s stock after acquiring an additional 10,097 shares during the period. Quantinno Capital Management LP’s holdings in Perrigo were worth $517,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Venturi Wealth Management LLC acquired a new stake in shares of Perrigo in the third quarter valued at approximately $56,000. KBC Group NV lifted its holdings in Perrigo by 25.1% during the 3rd quarter. KBC Group NV now owns 4,517 shares of the company’s stock valued at $118,000 after purchasing an additional 905 shares during the last quarter. Voisard Asset Management Group Inc. increased its holdings in shares of Perrigo by 9.7% in the third quarter. Voisard Asset Management Group Inc. now owns 5,100 shares of the company’s stock valued at $134,000 after purchasing an additional 450 shares during the last quarter. Atria Investments Inc bought a new position in shares of Perrigo in the third quarter valued at about $208,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Perrigo during the 2nd quarter worth about $213,000. Institutional investors own 95.91% of the company’s stock.
Insider Buying and Selling
In other Perrigo news, Director Jeffrey B. Kindler sold 17,598 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $28.27, for a total value of $497,495.46. Following the completion of the sale, the director now owns 5,409 shares of the company’s stock, valued at approximately $152,912.43. This trade represents a 76.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.70% of the stock is owned by insiders.
Perrigo Stock Performance
Perrigo (NYSE:PRGO – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.81 earnings per share for the quarter, hitting the consensus estimate of $0.81. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.12 billion. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The business’s quarterly revenue was down 3.2% on a year-over-year basis. During the same period last year, the company posted $0.64 EPS. Research analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current year.
Perrigo Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 17th. Stockholders of record on Friday, November 29th will be paid a $0.276 dividend. The ex-dividend date of this dividend is Friday, November 29th. This represents a $1.10 annualized dividend and a dividend yield of 4.02%. Perrigo’s dividend payout ratio is currently -94.02%.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. Jefferies Financial Group reiterated a “hold” rating and set a $30.00 target price (down previously from $50.00) on shares of Perrigo in a research note on Monday, September 23rd. StockNews.com raised shares of Perrigo from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $42.00 price target on shares of Perrigo in a report on Monday, September 30th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Perrigo presently has an average rating of “Moderate Buy” and an average price target of $37.00.
Read Our Latest Report on Perrigo
Perrigo Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Recommended Stories
- Five stocks we like better than Perrigo
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Airline Stocks – Top Airline Stocks to Buy Now
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Investing in the High PE Growth Stocks
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO – Free Report).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.